AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie's Botox Cosmetic has moved closer to FDA approval for a fifth aesthetic use: treating masseter muscle prominence. This potential approval is based on positive Phase 3 study results and aligns with AbbVie's strategy of expanding existing drug indications. While the company shows strong growth in immunology and neuroscience, concerns remain regarding its high debt-to-equity ratio, reliance on a few distributors, and potential impacts from the Inflation Reduction Act on drug pricing.